BAJAJ BROKING
Dr Reddy's Laboratories Ltd announced its consolidated financial results for Q3 FY24-25 on 23rd January 2025. The unaudited consolidated results, prepared under IFRS, highlighted robust revenue growth and steady profitability. Dr Reddy's Laboratories reported a 2% year-on-year increase in its consolidated net profit for the December quarter, amounting to ₹1,413 crore, compared to ₹1,379 crore in the same period last year.
The revenue from operations for Q3 FY25 was ₹8,359 crore, reflecting a 16% growth from ₹7,215 crore in the corresponding quarter of the previous financial year. The profit after tax (PAT) is attributable to the equity holders of the company.
Revenue Growth: ₹8,358.6 crore, a 16% YoY increase.
Net Profit: ₹1,413.3 crore, reflecting a 2% YoY growth.
Gross Margin: Improved slightly to 58.7% from 58.5% in Q3 FY24.
SG&A Expenses: ₹2,411.7 crore, up 19% YoY.
EBITDA: ₹2,298.2 crore, representing 27.5% of revenue.
R&D Spend: ₹665.8 crore, accounting for 8.0% of revenue.
Dr Reddy’s consolidated revenue rose to ₹8,358.6 crore, marking a robust 16% year-on-year growth. Net profit stood at ₹1,413.3 crore, driven by operational efficiency and contributions from the recently acquired Nicotine Replacement Therapy (NRT) business. The EBITDA margin remained strong at 27.5%, while R&D investments sustained innovation efforts in complex generics and biosimilars.
Revenue: ₹7,375.3 crore (+17% YoY).
North America: ₹3,383.4 crore (+1% YoY).
Europe: ₹1,209.6 crore (+143% YoY).
India: ₹1,346.4 crore (+14% YoY).
Emerging Markets: ₹1,435.8 crore (+12% YoY).
Growth was led by contributions from the NRT portfolio and new product launches.
Pharmaceutical Services and Active Ingredients (PSAI)
Revenue: ₹821.9 crore (+5% YoY).
Others
Revenue: ₹161.4 crore (+33% YoY).
Dr Reddy’s 16% revenue growth aligns with the pharmaceutical sector's optimistic projections, bolstered by increasing demand for generics and new launches. The 2% YoY increase in net profit reflects resilience amidst rising costs in SG&A and R&D.
Co-Chairman & MD, G.V. Prasad, commented:
“We delivered double-digit growth aided by our newly acquired NRT business, new launches, and improved operational efficiencies. We remain committed to addressing patient needs by advancing healthcare through access, affordability, and innovation”
The key priorities for the future include:
NRT Integration: Maximising value from the Nicotine Replacement Therapy business.
Product Launches: Expanding the pipeline with complex generics and biosimilars.
Geographical Growth: Strengthening presence in North America, Europe, and Emerging Markets.
Cost Efficiency: Enhancing operational and manufacturing efficiencies.
Healthcare Access: Continuing focus on affordability and innovation globally.
(All amounts in ₹ millions)
Sl No. | Particulars | Quarter Ended | Nine Months Ended | Year Ended | |||
31.12.2024 | 30.09.2024 | 31.12.2023 | 31.12.2024 | 31.12.2023 | 31.03.2024 | ||
(Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) | ||
1 | Revenues | 83,586 | 80,162 | 72,148 | 240,475 | 208,334 | 279,164 |
2 | Cost of Revenues | 34.534 | 32,393 | 29.945 | 97.310 | 86,210 | 115,557 |
3 | Gross Profit (I - 2) | 49,052 | 47,769 | 42,203 | 143,165 | 122,124 | 163,607 |
4 | Selling, General and Administrative Expenses | 24,117 | 23,007 | 20,228 | 69,815 | 56,725 | 77,201 |
5 | Research and Development Expenses | 6,658 | 7,271 | 5,565 | 20,122 | 15,996 | 22,873 |
6 | Impairment of Non-Current Assets, Net | 924 | 110 | 925 | 176 | 3 | - |
7 | Other Income, Net | (439) | (984) | (967) | (1,893) | (3,543) | (4,199) |
Total Operating Expenses | 30,332 | 30,218 | 24,936 | 88,969 | 69,354 | 95,878 | |
8 | Results from Operating Activities (1 - 4 + 5 + 6 + 7) | 18,720 | 17,551 | 17,267 | 54,196 | 52,770 | 67,729 |
Finance Income | 798 | 2,312 | 1,357 | 4,545 | 4,090 | 5,705 | |
Finance Expense | (818) | (757) | (394) | (2,173) | (1,118) | (1,711) | |
9 | Finance (Expense)/Income, Net | (20) | 1,555 | 963 | 2,372 | 2,972 | 3,994 |
10 | Share of Profit of Equity Accounted Investees, Net of Tax | 42 | 61 | 27 | 162 | 112 | 147 |
11 | Profit Before Tax (8 + 9 + 10) | 18,742 | 19,167 | 18,257 | 56,730 | 55,854 | 71,870 |
12 | Tax Expense, Net | 4,704 | 5,752 | 4,468 | 15,357 | 13,240 | 16,186 |
13 | Profit for the Period/Year (11 - 12) | 14,038 | 13,415 | 13,789 | 41,373 | 42,614 | 55,684 |
Attributable to: | |||||||
Equity Holders of the Parent Company | 14,133 | 12,553 | 13,789 | 40,606 | 42,614 | 55,684 | |
Non-controlling Interests | (95) | 862 | 767 | - | - | - | |
14 | Earnings Per Equity Share Attributable to Equity Shareholders of Parent | ||||||
Basic Earnings Per Share of Re. 1/- Each | 16.96 | 15.07 | 16.56 | 48.75 | 51.23 | 66.93 | |
Diluted Earnings Per Share of Re. 1/- Each | 16.94 | 15.05 | 16.54 | 48.68 | 51.14 | 66.81 |
Source: Dr Reddy’s Q3 Financial Results FY’24-25 Submitted on BSE
Dr Reddy's Laboratories is scheduled to announce its Q3 FY25 results on 23 January 2025. The pharmaceutical major is expected to report a 10% year-on-year (YoY) revenue growth, while profit after tax (PAT) is projected to remain flat at Rs 1,369 crore. Margins are likely to come under pressure due to subdued growth in the US base business and a decline in Revlimid sales.
Expected Dr Reddy’s Q3 FY25 Results
Revenue Growth: Estimated at 10% YoY to Rs 7,980 crore
Profit After Tax (PAT): Expected to remain flat at Rs 1,369 crore
EBITDA Margin: Likely to contract to 26.9% from 29.3% YoY
US Sales: Projected to remain stable YoY at $405-427 million
Domestic Sales: Expected to grow 14% YoY
Emerging Markets: Europe and Russia sales estimated to rise by 19% and 14% YoY, respectively
The estimates are based on analyst insights from The Economic Times and Moneycontrol.
Do you have a trading account app or demat account app?
You can open an account with Bajaj Broking in minutes.
Download the Bajaj Broking app now from Play Store or App Store.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading